Case Studies: Developer

Pioneering a first-in-class

Phase II-ready novel topical treatment

for Periodontitis

Introduction

Periodontal Disease is the most common inflammatory disease in adults worldwide. The global dental periodontics market was vauled at approximately US$15 billion in 2020 is projected to reach US$ 42 billion by 2026.

A spin-off from a highly reputable US dental research center was looking for partner(s) and/or investor(s) to finalize the development and commercialization of their product.

To achieve this, the company partnered with trifermed to design the business model and validate it through the interaction with key stakeholders aiming to identify strategic partner(s) that could take care of certain key activities.

Through trifermed’s structured methodology and strategic partnerships knowledge, the spin-off secured a co-development and licensing agreement covering Finland, Sweden, Denmark, Norway, Estonia, Latvia, Lithuania, Iceland and Russia.

Background

The spin-off sought partners that could:

            - To finance the development completion

            - Manufacture the final formulation

            - Lead the regulatory and commercialization process in the target markets

Trifermed was engaged to identify and facilitate these strategic partnerships, leveraging its extensive network, expertise in business development, and deep understanding of market dynamics in the pharmaceutical industry.​

Services Provided

  • Business Model Design, Strategy Discussion and Project Scope Definition​ –Partner Profile Definition

  • Partner Identification & Evaluation​: Contacting around 50 companies active in the dental space

  • Deal Structuring & Negotiation Support​

Outcomes & Future Development

As a result of trifermed’s work, the company secured a strategic co-development and licensing partnership in European countries with a knowleadgeable company that finalised the development of the product as a medical device and now many patients in Finland are benefiting from this dental innovation. These agreement enabled:​

  • Market Expansion: Entry into Europe through the expedited medical device (CE-mark obtained as a Class I device) pathway.

  • Strategic Alignment: A clear partnership structure ensuring shared objectives and long-term success.​

  • Operational Readiness: A well-defined collaboration framework with manufacturing established in EU opening the possibility to supply to other regions in the future.